Otonomy (OTIC) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Otonomy Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 7, 2016 4:14 PM ESTSAN DIEGO, March 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today reported financial results for the quarter and year ended December 31, 2015 and provided an update on its corporate activities and product pipeline. The company will host a webcast and conference call today at 4:30 p.m. ET to discuss recent highlights and financial results.
Fourth Quarter 2015 and Subsequent Highlights
Obtained FDA Approval and Initiated Commercial Launch of... More